Chinese contract research organization (CRO) Hangzhou Tigermed Consulting is joining hands with Singapore’s state-owned investment firm Temasek Holdings Limited to launch a USD-denominated investment fund that will back early and growth-stage startups in the biotechnology and CRO fields.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
